Ocul Surf

• 

  Publication Venue For

  • Fluorescein CorneoGraphy (FCG): Use of a repurposed fluorescein imaging technique to objectively standardize corneal staining..  27:77-79. 2023
  • Exposure keratopathy in patients undergoing invasive ventilation: Prevalence, severity, and the role of surface lubrication..  25:55-57. 2022
  • Meibomian gland dysfunction is suppressed via selective inhibition of immune responses by topical LFA-1/ICAM antagonism with lifitegrast in the allergic eye disease (AED) model..  21:271-278. 2021
  • Matrix metalloproteinase 9 positivity predicts long term decreased tear production..  19:270-274. 2021
  • Association of meibomian gland architecture and body mass index in a pediatric population..  18:657-662. 2020
  • Corrigendum to "TFOS DEWS II pathophysiology report" [Ocul. Surf. 15 (3) (2017) 438-510]..  17:842. 2019
  • Incidence and risk factors of symptomatic dry eye disease in Asian Malays from the Singapore Malay Eye Study..  15:742-748. 2017
  • Role of high resolution optical coherence tomography in diagnosing ocular surface squamous neoplasia with coexisting ocular surface diseases..  15:688-695. 2017
  • TFOS DEWS II iatrogenic report..  15:511-538. 2017
  • TFOS DEWS II pathophysiology report..  15:438-510. 2017
  • Acute and Chronic Ophthalmic Involvement in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis - A Comprehensive Review and Guide to Therapy. II. Ophthalmic Disease..  14:168-188. 2016
  • Lifitegrast, a Novel Integrin Antagonist for Treatment of Dry Eye Disease..  14:207-215. 2016
  • The Matrix Metalloproteinase 9 Point-of-Care Test in Dry Eye..  14:189-195. 2016
  • Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis--A Comprehensive Review and Guide to Therapy. I. Systemic Disease..  14:2-19. 2016
  • Treatment of blepharitis: recent clinical trials..  12:273-284. 2014